title: Major molecular response achieved with dasatinib in a CML patient with F317L BCR-ABL kinase domain mutation.
authors.forename: Edgar
authors.initials: E
authors.lastname: Faber
authors.forename: Renata
authors.initials: R
authors.lastname: Mojzikova
authors.forename: Radek
authors.initials: R
authors.lastname: Plachy
authors.forename: Sarka
authors.initials: S
authors.lastname: Rozmanova
authors.forename: Marek
authors.initials: M
authors.lastname: Stastny
authors.forename: Martina
authors.initials: M
authors.lastname: Divoka
authors.forename: Marie
authors.initials: M
authors.lastname: Jarosova
authors.forename: Karel
authors.initials: K
authors.lastname: Indrak
authors.forename: Vladimir
authors.initials: V
authors.lastname: Divoky
mesh_terms: D019943:Amino Acid Substitution / Q000502:physiology; D000970:Antineoplastic Agents / Q000627:therapeutic use; D020732:Cytogenetic Analysis; D000069439:Dasatinib; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D006801:Humans; D007930:Leucine / Q000235:genetics; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D010649:Phenylalanine / Q000235:genetics; D017434:Protein Structure, Tertiary / Q000235:genetics; D051562:Proto-Oncogene Proteins c-bcr / Q000737:chemistry / Q000235:genetics*; D011743:Pyrimidines / Q000627:therapeutic use*; D013844:Thiazoles / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D011743:Pyrimidines; D013844:Thiazoles; D010649:Phenylalanine; D051562:Proto-Oncogene Proteins c-bcr; D007930:Leucine; D000069439:Dasatinib